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Abstract
Background: The function of  the immune system in prostate cancer (PC) might promote carcinogenesis. PC is a common 
cancer in men.  Regulatory B cells (Bregs) are a new subtype of  B cells that have suppressive roles in the immune system. Inter-
leukin-10 (IL-10) is a dominant mediator of  immune suppression released by Bregs.
Objective: The purpose of  this research was to examine the frequency of  CD19+IL10+ B cells and IL-10 mRNA expression 
in patients with PC compared to patients with benign prostatic hyperplasia (BPH).
Methods: Forty paraffin tissue samples from patients with PC and 32 paraffin tissue samples from patients with BPH were en-
tered in this study. The immunohistochemistry staining was used to evaluate the pattern expression of  CD19 and IL-10 markers. 
IL-10 mRNA expression in fresh tissue was determined by real time-polymerase chain reaction (RT-PCR).
Results: The frequency of  CD19+IL-10+ B cells and IL-10 mRNA expression in PC patients were significantly higher than 
patients with BPH. Also, there was no meaningful relationship between the frequency of  IL-10+CD19+ B cells and gleason 
scores in patients with PC.
Conclusions: Our findings suggested that frequency of  IL-10+CD19+ B cells correlates with progressive stage of  PC.
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Introduction
Prostate cancer (PC) is the second most prevalent type 
of  male cancer-related death all over the world. In the tu-
mor microenvironment (TME), the complex cellular in-
teraction of  immune cells is involved in progression of1, 2. 
Recently, multiple diagnostic approaches including typical 
cancer staging (TNM), histological characteristics of  a 
prostate biopsy and prostate specific antigen (PSA) levels 
are considered to distinguish PC3. The immune system 
can promote cancer development4. Likewise, specific im-
mune cells exclusively release mediators in TME, leading 
to  immune system suppression5-7. There may be prognos-
tic markers in identifying tumor promoting immune cells 
in patients with PCa4. Recently, the performance of  reg-
ulatory B cells (Bregs) in immunosuppression has raised 
researchers’ attention as a key novel cell in cancer devel-
opment. In regard to the function, Bregs are highly sim-
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ilar to T regulatory cells (Tregs) and myeloid suppressive 
cells (MSC)8-10. Katz et al in 1974 recognized a different 
B cell subset, which delayed hypersensitivity on adoptive 
transfer11. Bregs decrease has been shown to exacerbate 
the signs of  disease in autoimmune diseases12, chronic in-
flammatory diseases13, chronic inflammatory disease, or 
increase tumor growth14. CD19+CD24hiCD38hi15 and 
CD19+IL-10+16 were extensively considered as markers 
for Bregs in human. Bregs can arrest the T-cell-mediat-
ed inflammatory response mainly via secreting IL-10. In 
regulating human cGVHD, the secretion of  IL-10 in B 
cells within the CD24hiCD27+ and CD27 high CD38 
high markers is essential16. IL-10-producing B cells can 
transform effector T cells to IL-10-producing suppres-
sive T cells for a longer period of  time through interac-
tion with CD4+CD25− T cells17,18. It has been shown 
that CD19−/− significantly enhances the function of  
T-cells19. The high presence of  CD5+CD19+IL-10+ 
Bregs in patients’ peripheral blood indicated that Bregs 
play an important role in carcinogenesis growth and 
prognosis20.
This research aimed at investigating the frequency of  
CD19+IL10+ B cells and IL-10 mRNA expression in PC 
patients compared to patients with benign prostatic hy-
perplasia (BPH) and their correlation with Gleason score.
Material and methods
Study population
The present study included all 72 patients diagnosed with 
biopsy obtained during prostatectomy at the Kashani 
hospital in Shahrekord. Before the study, none of  the 
patients received radiotherapy, radiation or other medi-
cal interventions. Patients with concurrent malignancies, 
autoimmune diseases or immune defects were excluded 
from the study. The control group was selected from the 
benign prostatic hyperplasia (BPH) from the patients who 
were undergone open prostatectomy for PC screening. 
The mean age was 65.63±14.42. Data on age is expressed 
mean ± SD and other data are reported as percentages.
Patients and tissue samples
The suitable Institutional Ethic Committees of  the 
Shahrekord University of  Medical Sciences approved the 
use of  human samples for this study. All patients gave 
written informed consent. Forty two patients with PC un-
derwent radical prostatectomy and 32 patients with BPH 
underwent open prostatectomy. Besides, 20 fresh tissue 
samples of  both PC and BPH were obtained for RNA 
extraction. Clinical information such as age, grade and 
stage were collected from medical files, and the names of  
participants remained confidential. The initial diagnosis 
of  the probability of  prostate cancer was checked using 
radiology photos, serum levels of  prostate-specific anti-
gen (PSA), and digital rectum exam (DRE) by a urolo-
gist. Then after obtaining samples by prostatectomy, the 
samples were transferred to the pathology lab and a de-
finitive diagnosis was made about the health or malignan-
cy of  the tissues. Also, in case of  malignancy, low grade 
and high grade samples were detected and reported by 
pathologist. The histological grade and stage of  PC was 
classified based on the Gleason system (GS Intermediate: 
<7; GS Progressive: >7) 21, 22. GS is a grading system that 
is determined by adding the most and second most com-
mon patterns ranging from 2 to 10 22.
Immunohistochemistry staining
Radical prostatectomy samples were cut and parts of  PC 
specimens were first embedded in 10% formalin buffered 
and then embedded in paraffin. The paraffin blocks were 
cut into 4μm thick pieces with microtomes. For immu-
nohistochemical staining, 4-µm serial sections were made 
and spread on poly-L-lysine- coated slides. Paraffin parts 
were dried and warmed in a 68°C oven overnight. The 
parts were then deparaffinized using three xylene mod-
ifications and rehydrated using a sequence of  alcohols 
(100%, 100%, 80% and 70%). For antigen retrieval the 
parts were inundated in citrate buffer (10mM Sodium Ci-
trate, 0.05% Tween 20, pH 6.0) and subjected to autoclav-
ing pressure and heat for 20 minutes to reveal concealed 
antigens for improved adhesion to antibodies in the next 
stages. In the next step protein blocks were added to the 
sections (ab94665, Abcam, UK) in order to block and hin-
der nonspecific background staining and were incubated 
for 2 hours. After washing the parts with distilled water, 
Anti-human CD19 mouse antibody (ab31947, ebiosci-
ence, UK) at a 1:200 dilution, anti-human IL-10 Rabbit 
antibody (ab34843, Abcam, UK) at a 1:400 dilution was 
applied. Afterwards, the parts were then put overnight in 
a suitable moisture chamber at 4 °C. The next day, after 
rinsing the slides in TBST buffer, 3% H2O2 in TBS for 15 
min was applied to parts for preventing endogenous per-
oxidase activity. Later, Biotinylated goat anti-rabbit and 
mouse IgG (ab93697, Abcam, UK) which is also called 
secondary antibody was added and the sections were in-
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cubated for 1 hour at room temperature in moist cham-
ber. After the incubation time, the sections were incubat-
ed with Streptavidin Peroxidase Plus at room temperature 
for 10 minutes. Next, the chromogenic segment called 
3-diaminobenzidine tetrahydrochloride (DAB) was incu-
bated for 10 minutes (ab94665, Abcam, UK). After wash-
ing with the TBST buffer, parts were placed with Meyer's 
hematoxyline for 1 minute and washed with cold water 
and mounted. Human tonsil tissue was used as positive 
control for CD19 and IL-10. Sections without any pri-
mary antibody were considered as negative control. The 
numbers of  CD19 and IL-10 cells were determined in 10 
high-power fields by calculating positive cells in the entire 
tissue area. Outcomes were expressed as the mean value 
of  all tested patients in any group.
RNA extraction and Real-time PCR (RT-PCR)
Twenty fresh tissue biopsies containing 10 PC and 10 
BPH samples were taken from radical prostatectomy and 
open prostatectomy. Before analysis, specimens were held 
at -70 ° C. TRIzol ® Plus RNA reagent extracted the total 
RNA. The concentration of  each RNA sample was cal-
culated by Thermo Scientific TM NanoDrop 2000. Com-
plementary DNAs (cDNA) were produced with reverse 
transcriptase (RT) using the First Strand cDNA Synthe-
sis Kit (Fermentas Life Sciences, cat- K1622) with 2.5 μg 
RNA at a 20 μL reaction volume. The amplification of  
IL-10 cDNA in a Rotorgene 3000 (Corbett Life Science) 
was performed using the SYBR Green RT-PCR method. 
The primer sequences of  IL-10 applicated in the RT-PCR 
include: IL-10 5`-TCAAGGCGCATGTGAACTC-3` 
(Forward), 5`-CGGCCTTGCTCTTGTTTTC-3` (Re-
verse) and  GAPDH 5`-TTCACCACCATGGAGAAG-
GC-3` (Forward), 5`-CCCTTTTGGCTCCACCCT-3` 
(Reverse) as internal control (housekeeping genes) was 
used. Also, each sample was accomplished in duplicate. 
RT-PCR reactions were performed in a total volume of  
20 μl containing of  1 µL diluted cDNA, 1 µL of  each oli-
gonucleotide primers, 7 µL nuclease free H2O and 10 µL 
2X SYBR Green Master Mix. Negative control samples 
were constructed by deleting the diluted cDNA from the 
reaction mixture.  RT-PCR was started with a 5-minute 
denaturation stage at 95 ° C and next in 35  amplification 
cycles that each cycle was included of  95ºC denaturation 
at 10s, 60ºC annealing  at 20s, and 72ºC extension at 30s. 
At the melting step, which is the last stage quality of  ex-
amination was determined.
Statistical analysis
Analysis was carried out in duplicate and all data were 
shown as mean ± SD. The usual data distribution was 
validated by the normality check of  Shapiro-Wilk. T test 
(To compare the two samples) or Tukey post hoc test (for 
multiple comparisons) evaluated quantitative data, com-
paring diseased groups with a different GraphPad Prism 
software version 8 control group (GraphPad Software, 
La Jolla, CA, USA). Pearson's parametric information as-
sociation analysis was used to determine the relationship 
between variables. The relationship between gene expres-
sion levels and PC existence was evaluated using a multi-
variate logistic regression model. Where the P-value was 
less than 0.05, statistical significance was considered.
Results
Increased expression of  IL-10 in PC (tumor tissues) 
compared with BPH
In our analysis, real-time PCR of  20 PC samples and 20 
BPH samples assessed the mRNA expression of  IL-10. 
The IL-10 mRNA was significantly higher in PC patients 
compared with BPH group (Fig. 1A; P < 0.0001). ). If  
the mean of  IL-10 expression in tumor tissue is 4.80 and 
the mean of  IL-10 expression in non-tumoral tissue is 
1.35 then the difference in the IL-10 expression in tu-
mor tissue compared with non-tumoral tissue is 3.55-fold 
(4.08/1.35). The IL-10 gene expression in both interme-
diate and progressive groups of  PC was more than that in 
the BPH group; however, there was no significant differ-
ence between intermediate and progressive groups (Fig. 
1).
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Figure 1. IL-10 mRNA level was evaluated in radical prostatectomy specimens. A) IL-10 gene 
expression in 20 PC samples and 20 BPH samples was shown. The real-time PCR results were 
standardized for human IL-10 versus GAPDH. B) In prostatectomy samples, the gene IL-10 was 
significantly over-expressed in intermediate and progressive PC patients rather than BPH. P-values less 
than 0.05 is statistically significant. PC: Prostate Cancer; BPH: benign prostatic hyperplasia. 
The frequency of  CD19+IL-10+ B cells was in-
creased in prostatectomy tissue of  PC
The prostatectomy tissues were immunostained with an-
ti-CD19 and anti-IL-10 antibodies to detect Breg cells in 
samples (Fig.2). We observed that there is a significant 
increase in the frequency of  CD19+IL-10+ B cells PC 
tissues than BPH tissues (Fig.3A; P =0.0014). Also, the 
number of  CD19+IL-10+ B cells in intermediate and 
progressive groups of  PC was higher than the BPH 
group (Fig.3B; P = 0.0258 and 0.0225, respectively). The 
presence of  PCs was positively correlated with the high 
frequency of  IL-10 and CD19+IL-10+ B cells in mul-
tivariable logistic regression analysis. (P = 0.033, 0.014) 
(Table 2). Per 1 unite rise in frequency of  CD19+IL-10+ 
B cells, the possibility of  PC development was 1.34 times 
higher than the control group.
 
Figure 2. Assessment of prostatectomy tissues in immunohistochemistry for CD19 and IL-10 markers. 
Formalin-fixed and paraffin-embedded were stained with anti-CD19 and anti-IL-10 antibodies. Sequence 
sections of tissue were used to immunostaining CD19 and IL-10. CD19+IL-10+ B cells dominantly 
appear in the PC tissues. 
 
 
 
Figure 3. The frequency of CD19+IL-10+ B cells was shown. The number of CD19+IL-10+ B cells in the 
PC group was 1.5 higher than BPH group. P-values less than 0.05 is statistically significant. PC: Prostate 
Cancer; BPH: benign prostatic hyperplasia. 
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Figure 3. The frequency of CD19+IL-10+ B cells is shown. The number of CD19+IL-10+ B cells in the 
PC group was 1.5 higher than BPH group. P-values less than 0.05 is statistically significant. PC: Prostate 
Cancer; BPH: benign prostatic hyperplasia. 
  All (n= 72) 
FFPE samples PCa/BPH 72-40/32 
 Fresh samples PCa/BPH 20-10/10 
Mean age ± SD, years  PCa/BPH 77.38/73.61 (p-value was not significant) 
  
≤70 y 
  
25/72  
  
>70 y 47/72 
Pathologic Gleason score   
<7 14/42  
  
≥7 28 /42 
Median PSA ( ng/mL)   
<4 ng/ml 16/72 
4-10 ng/ml 
>4 ng/ml 
29/72 
27/72 
Table 1. Clinical and pathological characteristics                                            
PCa, prostate cancer; BPH, benign prostate hyperplasia; FFPE, Formalin-fixed paraffin embedded; 
PSA, prostate-specific antigen 
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Discussion
PC is one of  the most generally diagnosed cancers among 
men all over the world, and mortality has been on the rise 
23. The effects of  immunotherapeutic strategies are de-
pendent on interaction of  tumor cells and host immune 
response 24. The lymphocytes that are infiltrated in tumor 
tissue have the potential to be used as the positive prog-
nostic relation in cancer. An analysis of  50 high-grade PC 
transurethral prostate samples found that the rate of  man-
ually counted CD20+ B cells in the PC was significant-
ly higher than in the control group 25. This investigation 
probably indicates that B cells may have an effective role 
in cancer development tumor genesis process. Another 
study showed that B cells can generate different cytokines 
such as lymphotoxin, which is able to activate signaling 
pathways in tumor cells of  patients  with castration-resis-
tant prostate cancer (CRPC) 26. Shimabukuro-Vornhagen 
et al. suggested that a decrease in the number of  B cells in 
colorectal cancer and an enhanced proportion of  Bregs 
that contribute to metastasis may represent immune es-
cape 27.
Several studies on various lymphoid malignancies in hu-
mans have shown that malignant B cells can act as Bregs 
that repress anti-tumor immune responses with their 
suppressive ligands 28, 29. Overall, these studies on B cells 
can indicate that these cells have regulatory properties 
and have a direct effect on cancer growth 30. Our results 
demonstrated that the frequency of  CD19+IL-10+ B 
cells and IL-10 gene expression in PC patients were sig-
nificantlyhigher than the patients with benign prostatic. 
In addition, the exponential rate of  logistical regression 
showed that CD19+IL-10+ B cells and IL-10 cytokine 
could play a role in maintaining prostate cancer. Our find-
ings suggest that the PC environment plays an import-
ant role in the induction of  CD19+IL-10+ B cells dif-
ferentiation or infiltration, which is confirmed by breast 
cancer cell studies that these cells can provoke Bregs ex-
pression in mice spleens 31. According to available data, 
IL-10+CD19+ B cells accumulate in tumor areas and 
peri-tumor environment 32. An immunohistochemical 
study on radical prostatectomy indicated the high fre-
quency of  B cell in malignant tissue against benign tissue 
33. These findings suggest that B lymphocytes are critical 
in response to antitumor immunity and can differenti-
ation to Bregs. PC microenvironment is more likely to 
be immunosuppressive 34. Low cytolytic activity of  NK 
cells was detected in prostate tumor milieu35. The high 
secretion of  transforming growth factor beta (TGF-β) by 
prostate tissue inhibits NK cells and lymphocytes func-
tion and migration 36. Furthermore, the agglomeration of  
Tregs and Th17 lymphocytes down-regulates antitumor 
immunity in PC 37, 38. A research by Zhou et al. found that 
factors released by lung cancer and infiltrated immune 
cells can play a significant role in Breg cell growth and the 
extent of  inflammation 39. Our results presumably have 
  Regression 
coefficient 
(β) 
Standard error P-value 95% C.I for Eep (B) 
  
Lower Upper 
Breg cell 
  
1.342922 0.1861459 0.033* 0.0231172 0.5665123 
Frequency of IL-10 1.586061 0.2976891 0.014* 0.0933858 0.8291207 
Frequency of  
CD19 
1.086774 0.1608512 0.574 -0.2068765 0.3733041 
Table 2. Coefficients of the logistic regression analysis for the existence of PC. 
* The presence of PC was significantly correlated with high level of IL-10 and Breg 
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demonstrated that the expression of  IL-10 has a relation-
ship with the poor prognosis of  cancer. IL-10 is an im-
portant mediator of  immune suppression by Bregs40. A 
recent study of  tongue squamous cell carcinoma (TSCC) 
found that IL-10+CD19+ B cells played an important 
role in transforming CD4+ T cells into Tregs via IL-10 
secretion and worse prognosis in patients with TSCC 32. 
There are indications that Bregs can produce Tregs via 
cell contact and IL-10 secretion40. Also, the study showed 
that Bregs suppressor is IL-10, CD80, and CD86 depen-
dent, but not TGF-β in humans9, which was constant 
with our conclusions that IL-10 is critical cytokine in can-
cer. An analysis on the animal model of  breast cancer, 
however, found that the conversion of  CD4+ T cells to 
Tregs was associated with increased TGF-β levels rather 
than IL-10  31.  Perhaps IL-10+CD19+ B cells through 
IL-10 are capable of  suppressing immune cells in tumor 
microenvironment and promote metastasis through in-
teractions with Tregs. Our findings suggested that an en-
hanced frequency of  IL-10+CD19+ B cells may promote 
tumor progression in patients with PC through the se-
cretion of  anti-inflammatory mediators. Altogether, the 
use of  CD19+IL-10+ B cells in cancer treatment may be 
much welcomed in the future, especially in the field of  
immune response to tumors.
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